Search research articles
Contact Us
Filters
Showing results (1-10 of 38) with videos related to
Page
of 4
Sort By:
Arthritis and Rheumatism
|
February 2, 2012
Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice
Elizabeth Pigott, Laura Mandik-Nayak
Immunologic Research
|
August 18, 2005
Initiation of an autoimmune response: insights from a transgenic model of rheumatoid arthritis
Laura Mandik-Nayak, Paul M Allen
Clinical Medicine Insights. Pathology
|
November 29, 2016
IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity
Lauren M F Merlo, Laura Mandik-Nayak
Current Directions in Autoimmunity
|
November 1, 2002
B cell anergy and systemic lupus erythematosus
Su-jean Seo, Laura Mandik-Nayak, Jan Erikson
Methods in Cell Biology
|
October 17, 2025
Autoimmune arthritis: Transgenic mouse models and methods
Lauren M F Merlo, Weidan Peng, Laura Mandik-Nayak
Immunotherapy
|
July 20, 2010
Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation
Alexander J Muller, Laura Mandik-Nayak, George C Prendergast
Frontiers in Immunology
|
May 2, 2022
Impact of IDO1 and IDO2 on the B Cell Immune Response
Lauren M F Merlo, Weidan Peng, Laura Mandik-Nayak
The Journal of Experimental Medicine
|
August 2, 2006
Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help
Laura Mandik-Nayak, Jennifer Racz, Barry P Sleckman, et al.
Current Opinion in Immunology
|
September 9, 2008
Role of B cells in systemic lupus erythematosus and rheumatoid arthritis
Laura Mandik-Nayak, Natalie Ridge, Michele Fields, et al.
Clinical Pathology (Thousand Oaks, Ventura County, Calif.)
|
September 14, 2020
B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2,3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model
Lauren Mf Merlo, Jessica Bowers, Tony Stefanoni, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 38) with videos related to
Sort By:
Page
of 4
Arthritis and Rheumatism
|
February 2, 2012
Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice
Elizabeth Pigott, Laura Mandik-Nayak
Immunologic Research
|
August 18, 2005
Initiation of an autoimmune response: insights from a transgenic model of rheumatoid arthritis
Laura Mandik-Nayak, Paul M Allen
Clinical Medicine Insights. Pathology
|
November 29, 2016
IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity
Lauren M F Merlo, Laura Mandik-Nayak
Current Directions in Autoimmunity
|
November 1, 2002
B cell anergy and systemic lupus erythematosus
Su-jean Seo, Laura Mandik-Nayak, Jan Erikson
Methods in Cell Biology
|
October 17, 2025
Autoimmune arthritis: Transgenic mouse models and methods
Lauren M F Merlo, Weidan Peng, Laura Mandik-Nayak
Immunotherapy
|
July 20, 2010
Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation
Alexander J Muller, Laura Mandik-Nayak, George C Prendergast
Frontiers in Immunology
|
May 2, 2022
Impact of IDO1 and IDO2 on the B Cell Immune Response
Lauren M F Merlo, Weidan Peng, Laura Mandik-Nayak
The Journal of Experimental Medicine
|
August 2, 2006
Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help
Laura Mandik-Nayak, Jennifer Racz, Barry P Sleckman, et al.
Current Opinion in Immunology
|
September 9, 2008
Role of B cells in systemic lupus erythematosus and rheumatoid arthritis
Laura Mandik-Nayak, Natalie Ridge, Michele Fields, et al.
Clinical Pathology (Thousand Oaks, Ventura County, Calif.)
|
September 14, 2020
B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2,3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model
Lauren Mf Merlo, Jessica Bowers, Tony Stefanoni, et al.
Page
of 4